Japan Approves Leqembi, All Eyes Now On Extended Pricing Discussions
Concizumab, Tenapanor, Others Get Nods
Executive Summary
Japan's latest batch of product approvals includes high-profile Alzheimer's drug Leqembi (lecanemab), along with Alhemo (concizumab) for hemophilia, Phozevel (tenapanor) for hyperphosphatemia and others. Eyes are now on the shape of use guidelines and monitoring requirements for Leqembi, along with how its extended NHI reimbursement pricing process will develop. All going well, it could reach the market by the end of the year.
You may also be interested in...
Japan’s CEA Scheme: How It Works And Impact So Far
Japan has announced the latest evaluation results under its cost effectiveness assessment scheme. But how does it work and how much have prices been revised so far under the four-year-old program following discussions between pharma firms and authorities?
Japan Pricing Update: Wegovy Finally Listed, Upcoming Special Cuts For Imfinzi, Polivy
Japan adds a batch of new drugs, including Wegovy, to the national health insurance reimbursement tariff, but discussions over Leqembi for Alzheimer’s are still ongoing, with indications that repricing could be possible if demand expands quickly.
PhRMA's Narasimhan Asks Japan To Reform Pricing Policies
Pointing to what it says is decreased R&D in Japan in contrast to the global market, PhRMA has again urged the country to revise its drug pricing policies and support innovation, while cautiously welcoming new moves to waive a requirement for Phase I trials in the country.